Get the Stockscreener App
108.62
1.06%
1.14
After Hours:
109.07
0.45
+0.41%
Mirum Pharmaceuticals Inc stock is traded at $108.62, with a volume of 648.65K.
It is up +1.06% in the last 24 hours and up +15.20% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$107.48
Open:
$107.77
24h Volume:
648.65K
Relative Volume:
0.89
Market Cap:
$6.50B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-67.37
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
+3.35%
1M Performance:
+15.20%
6M Performance:
+51.26%
1Y Performance:
+117.54%
1-Day Range:
$106.43
$109.05
1-Week Range:
$102.50
$109.28
52-Week Range:
$36.88
$109.28
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
108.62 | 6.44B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum Pharmaceuticals Files For Offering Of Up To 8.96 Million Shares Of Common Stock By The Selling Stockholders - TradingView
Mirum (MIRM) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Mirum Pharmaceuticals’ Q4 2025 revenue exceeds expectations - Investing.com India
Mirum Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Mirum Pharmaceuticals earnings up next as pipeline readouts loom - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Powerhouse with 9.63% Potential Upside - DirectorsTalk Interviews
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Mirum Pharmaceuticals, Inc. has officially registered a public offering plan of common stock initiated by selling shareholders. - Bitget
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its 115% One-Year Surge? - Yahoo Finance
Insights Ahead: Mirum Pharmaceuticals's Quarterly Earnings - Benzinga
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - bdtonline.com
Will Mirum Pharmaceuticals Inc. stock hit new highs in YEARJuly 2025 Snapshot & Weekly High Return Stock Forecasts - mfd.ru
Mirum Pharmaceuticals (NASDAQ:MIRM) Research Coverage Started at Royal Bank Of Canada - Defense World
Portfolio Recap: Will Mirum Pharmaceuticals Inc stock hit new highs in YEARJuly 2025 Review & Risk Controlled Daily Plans - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Raised to "Moderate Buy" at Royal Bank Of Canada - MarketBeat
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD By Investing.com - Investing.com Canada
Earnings Recap: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 Trends & Free Community Consensus Stock Picks - baoquankhu1.vn
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 - Bluefield Daily Telegraph
Drugmaker Mirum sets Feb. 25 call on 2025 results - Stock Titan
RBC Capital Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Outperform Recommendation - Nasdaq
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week HighTime to Buy? - MarketBeat
Mirum Can Sustain Revenue Growth with Multiple Catalysts, RBC Says - marketscreener.com
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance
Mirum Pharmaceuticals (MIRM) Expected to Announce Earnings on Wednesday - MarketBeat
Saira Ramasastry, Mirum director, sells $204k in shares By Investing.com - Investing.com Canada
Saira Ramasastry, Mirum director, sells $204k in shares - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Gem with 11.25% Upside Potential - DirectorsTalk Interviews
TimesSquare Capital Management LLC Makes New $22.04 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Is Mirum Pharmaceuticals Inc. a turnaround storyDollar Strength & Real-Time Stock Price Movement Reports - mfd.ru
Why Mirum Pharmaceuticals Inc. stock is trending among retail traders - mfd.ru
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy - ChartMill
What are analysts’ price targets for Mirum Pharmaceuticals Inc.Earnings Summary Report & Weekly Sector Rotation Insights - mfd.ru
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Mirum Pharmaceuticals Inc. benefit from AI trendsShare Buyback & Expert Verified Stock Movement Alerts - mfd.ru
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MEXC
Mirum Pharmaceuticals Grants Stock Awards to New Employees - Intellectia AI
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup - ChartMill
Candriam S.C.A. Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals expands portfolio in rare disease drug focus - Traders Union
Gap Down: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Health Canada approves Livmarli for PFIC and ALGS - The Pharma Letter
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Penserra Capital Management LLC - MarketBeat
Sentiment Review: Is Mirum Pharmaceuticals Inc a turnaround storyFed Meeting & Safe Entry Trade Signal Reports - baoquankhu1.vn
Health Canada LIVMARLI Decision And Bluejay Deal Shape Mirum Outlook - Yahoo Finance
Mirum Pharmaceuticals says Health Canada authorizes Livmarli for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - BioSpace
Mirum Pharmaceuticals Stumbles on Health Canada Approval - Baystreet.ca
Mirum Pharmaceuticals' Tablet Formulation of its Cholestasic Pruritus Treatment Livmarli Approved in Canada - marketscreener.com
for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Business Wire
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - AOL.com
Hot Picks: Small-cap pharma stocks in focus as key drug approvals near - BNN Bloomberg
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):